Is hypofractionated radiotherapy used to treat soft tissue sarcomas? Assessment of practices using the NETSARC network.

Autor: Agnoux E; Radiation Department, Institut de Cancérologie de Lorraine, 54519 Vandœuvre-lès-Nancy, France. Electronic address: e.agnoux@nancy.unicancer.fr., Stefani A; Radiation Department, Institut de Cancérologie de Lorraine, 54519 Vandœuvre-lès-Nancy, France., Sahki N; Data and Biostatistics Department, Institut de Cancérologie de Lorraine, 54519 Vandœuvre-lès-Nancy, France., Meknaci É; Medical Physics Department, Institut de Cancérologie de Lorraine, 54519 Vandœuvre-lès-Nancy, France., Jolnerovski M; Radiation Department, Institut de Cancérologie de Lorraine, 54519 Vandœuvre-lès-Nancy, France.

Publikováno v: Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique [Cancer Radiother] 2024 Dec; Vol. 28 (8), pp. 677-685. Date of Electronic Publication: 2024 Nov 21.

Long-term Results of Hypofractionated Radiotherapy With Intra-prostatic Boosts in Men With Intermediate- and High-risk Prostate Cancer: A Phase II Trial.

Autor: Chatterjee R; Department of Radiotherapy, Clatterbridge Cancer Centre, 65 Pembroke Place, Liverpool, UK. Electronic address: rhiju.chatterjee@nhs.net., Chan J; Department of Radiotherapy, Clatterbridge Cancer Centre, 65 Pembroke Place, Liverpool, UK., Mayles H; Department of Radiotherapy, Clatterbridge Cancer Centre, 65 Pembroke Place, Liverpool, UK., Cicconi S; Swiss Tropical and Public Health Institute Kreuzstrasse 2, 4123 Allschwil, Switzerland., Syndikus I; Department of Radiotherapy, Clatterbridge Cancer Centre, 65 Pembroke Place, Liverpool, UK.

Publikováno v: Clinical oncology (Royal College of Radiologists (Great Britain)) [Clin Oncol (R Coll Radiol)] 2024 Dec; Vol. 36 (12), pp. e473-e482. Date of Electronic Publication: 2024 Aug 22.

Late Urinary Toxicity After Extreme or Moderate Hypofractionated Prostate Radiation Therapy in Patients With Prior Transurethral Resection of Prostate.

Autor: Singh M; Departments of Radiation Oncology., Maitre P; Departments of Radiation Oncology., Krishnan A; Departments of Radiation Oncology., Adsul K; Departments of Radiation Oncology., Mini Sreekumar S; Departments of Radiation Oncology., Chauhan H; Departments of Radiation Oncology., Bishnu PN; Departments of Radiation Oncology., Phurailatpam R; Department of Medical Physics., Singh P; Clinical Research Secretariat., Kamble D; Clinical Research Secretariat., Bakshi G; Department of Surgical Oncology, Tata Memorial Hospital and Advanced Centre for Treatment Research and Education in Cancer (ACTREC), Homi Bhabha National Institute (HBNI), Mumbai, India., Pal M; Department of Surgical Oncology, Tata Memorial Hospital and Advanced Centre for Treatment Research and Education in Cancer (ACTREC), Homi Bhabha National Institute (HBNI), Mumbai, India., Arora A; Department of Surgical Oncology, Tata Memorial Hospital and Advanced Centre for Treatment Research and Education in Cancer (ACTREC), Homi Bhabha National Institute (HBNI), Mumbai, India., Misra A; Department of Surgical Oncology, Tata Memorial Hospital and Advanced Centre for Treatment Research and Education in Cancer (ACTREC), Homi Bhabha National Institute (HBNI), Mumbai, India., Prakash G; Department of Surgical Oncology, Tata Memorial Hospital and Advanced Centre for Treatment Research and Education in Cancer (ACTREC), Homi Bhabha National Institute (HBNI), Mumbai, India., Murthy V; Departments of Radiation Oncology. Electronic address: vmurthy@actrec.gov.in.

Publikováno v: International journal of radiation oncology, biology, physics [Int J Radiat Oncol Biol Phys] 2024 Nov 15; Vol. 120 (4), pp. 1011-1020. Date of Electronic Publication: 2024 Jun 20.

Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I Non-Small Cell Lung Cancer: The LUSTRE Phase 3 Randomized Clinical Trial.

Autor: Swaminath A; Department of Oncology, McMaster University, and the Division of Radiation Oncology Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada., Parpia S; Department of Oncology, McMaster University, Hamilton, Ontario, Canada., Wierzbicki M; Juravinski Cancer Centre, Department of Medical Physics, McMaster University, Hamilton, Ontario, Canada., Kundapur V; Saskatchewan Cancer Agency, Department of Radiation Oncology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada., Faria S; Department of Radiation Oncology, McGill University Health Centre, Montreal, Quebec, Canada., Okawara GS; Department of Oncology, McMaster University, and the Division of Radiation Oncology Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada., Tsakiridis TK; Department of Oncology, McMaster University, and the Division of Radiation Oncology Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada., Ahmed N; Section of Radiation Oncology, Department of Radiology, Rady Faculty of Health Sciences, University of Manitoba and CancerCare Manitoba Research Institute, Winnipeg, Manitoba, Canada., Bujold A; Département de Radio-oncologie Clinique-Enseignement-Recherche, Centre intégré universitaire de soins et services sociaux de l'Est-de-l'Île-de-Montréal - Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada., Hirmiz K; Department of Radiation Oncology, Windsor Regional Cancer Centre, Windsor, Ontario, Canada., Owen T; Department of Oncology, Queen's University, Cancer Centre of Southeast Ontario at Kingston Health Sciences Centre, Kingston, Ontario, Canada., Leong N; Allan Blair Cancer Centre, Department of Radiation Oncology, University of Saskatchewan, Regina, Saskatchewan, Canada., Ramchandar K; Department of Oncology, Northern Ontario School of Medicine, Thunder Bay, Ontario, Canada., Filion E; Radiation Oncology Department, Centre Hospitalier de l'Université de Montréal, Notre Dame Hospital, Montreal, Quebec, Canada., Lau H; Department of Oncology, University of Calgary, Calgary, Alberta, Canada., Gabos Z; Department of Oncology, University of Alberta, Edmonton, Alberta, Canada., Thompson R; Department of Radiation Oncology, Dalhousie University, Saint John, New Brunswick, Canada., Yaremko B; Department of Radiation Oncology, Western University, London, Ontario, Canada., Mehiri S; Département de Radio-oncologie, CISSS Montérégie, Hôpital Charles Lemoyne, Montreal, Quebec, Canada., Louie AV; Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada., Quan K; Department of Oncology, McMaster University, and the Division of Radiation Oncology Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada., Levine MN; Department of Oncology, McMaster University, Hamilton, Ontario, Canada., Wright JR; Department of Oncology, McMaster University, and the Division of Radiation Oncology Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada., Whelan TJ; Department of Oncology, McMaster University, and the Division of Radiation Oncology Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada.

Publikováno v: JAMA oncology [JAMA Oncol] 2024 Nov; Vol. 10 (11), pp. 1571-1575. Date of Electronic Publication: 2024 Sep 19.

Acute toxicity of hypofractionated radiotherapy for Japanese breast cancer patients after surgery: a single center prospective observational study (HyPORT-BC).

Autor: Nakamura M; Department of Radiation Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. masanaka@east.ncc.go.jp.; Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo, Japan. masanaka@east.ncc.go.jp., Fujisawa T; Department of Radiation Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan., Oyoshi H; Department of Radiation Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan., Zhou Y; Department of Radiation Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan., Fukushi K; Department of Radiation Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan., Hirata H; Department of Radiation Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan., Tomizawa K; Department of Radiation Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan., Motegi A; Department of Radiation Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan., Hojo H; Department of Radiation Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan., Wakabayashi M; Clinical Research Support Office Biostatistics Section, National Cancer Center Hospital East, Chiba, Japan., Kano K; Department of Radiological Technology, National Cancer Center Hospital East, Chiba, Japan., Ohno R; Department of Radiological Technology, National Cancer Center Hospital East, Chiba, Japan., Nakamura A; Department of Radiation Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan., Yamaguchi M; Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo, Japan.; Department of Radiology, National Cancer Center Hospital East, Chiba, Japan., Zenda S; Department of Radiation Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.

Publikováno v: Breast cancer (Tokyo, Japan) [Breast Cancer] 2024 Nov; Vol. 31 (6), pp. 1176-1181. Date of Electronic Publication: 2024 Aug 08.